» Articles » PMID: 20026136

Intravenous Levetiracetam in the Rat Pilocarpine-induced Status Epilepticus Model: Behavioral, Physiological and Histological Studies

Overview
Specialties Neurology
Pharmacology
Date 2009 Dec 23
PMID 20026136
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Status epilepticus is a neurological emergency associated with neuronal injury, lasting behavioral disturbance, and a high rate of mortality. Intravenous levetiracetam (LEV), an anti-epileptic drug approved to treat partial seizures, has recently been introduced. We sought to determine the effect of LEV administered intravenously in a chemoconvulsant model of status epilepticus.

Methods: We examined the effect of intravenous LEV in the rat lithium-pilocarpine model of status epilepticus. Ten or 30 min after the onset of behavioral status epilepticus, animals were treated with LEV (200-1200 mg/kg i.v.) administered in a single bolus. Behavioral responses were recorded. Selected animals had continuous EEG recording before, during and after the administration of LEV. Some animals were sacrificed 24 h after the experiment and processed for histochemical assessment of neuronal injury.

Results: When administered 30 min after the onset of behavioral epileptic seizures, transient attenuation of ictal behavior was observed in animals treated with 800 mg/kg or more of LEV. The duration of behavioral attenuation increased sharply as the dose rose to 1000 mg/kg or higher, from a mean of 4-23.6 min. When administered 10 min after seizure onset, 400 mg/kg of LEV resulted in transient ictal behavioral attenuation, and higher doses caused relatively longer periods of attenuation. Pretreatment with LEV prior to pilocarpine also delayed the onset of seizures. EEG recordings, however, showed no significant attenuation of ictal discharge. By contrast, TUNEL staining demonstrated less neuronal injury in hippocampii and other limbic structures in animals that responded behaviorally to LEV.

Conclusions: Intravenous administration of LEV in a chemoconvulsant model of status epilepticus results in attenuation of behavioral manifestations of seizure discharge and in reduction of neuronal injury but does not significantly alter ictal discharge recorded by EEG.

Citing Articles

Anticonvulsant Effects of Synthetic -(3-Methoxybenzyl)oleamide and -(3-Methoxybenzyl)linoleamide Macamides: An In Silico and In Vivo Study.

Vera-Lopez K, Aguilar-Pineda J, Moscoso-Palacios R, Davila-Del-Carpio G, Manrique-Murillo J, Gomez B Molecules. 2025; 30(2).

PMID: 39860203 PMC: 11767965. DOI: 10.3390/molecules30020333.


Gaertn as a Potential Alternative Therapy for the Treatment of Epilepsy: An Animal Study.

Rivadeneyra-Dominguez E, Zamora-Bello I, Rodriguez-Landa J, Ortega-Garcia A, Rosales-Sanchez O Dose Response. 2024; 22(3):15593258241282018.

PMID: 39247123 PMC: 11378198. DOI: 10.1177/15593258241282018.


Levetiracetam Mechanisms of Action: From Molecules to Systems.

Contreras-Garcia I, Cardenas-Rodriguez N, Romo-Mancillas A, Bandala C, Zamudio S, Gomez-Manzo S Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455472 PMC: 9030752. DOI: 10.3390/ph15040475.


Levetiracetam and N-Cadherin Antibody Alleviate Brain Pathology Without Reducing Early Epilepsy Development After Focal Non-convulsive Status Epilepticus in Rats.

Avdic U, Ahl M, Andersson M, Ekdahl C Front Neurol. 2021; 12:630154.

PMID: 33716930 PMC: 7943745. DOI: 10.3389/fneur.2021.630154.


Severe hypoglycemia-induced sudden death is mediated by both cardiac arrhythmias and seizures.

Reno C, Skinner A, Bayles J, Chen Y, Daphna-Iken D, Fisher S Am J Physiol Endocrinol Metab. 2018; 315(2):E240-E249.

PMID: 29486140 PMC: 6139495. DOI: 10.1152/ajpendo.00442.2017.


References
1.
Mazarati A, Baldwin R, Klitgaard H, Matagne A, Wasterlain C . Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res. 2004; 58(2-3):167-74. DOI: 10.1016/j.eplepsyres.2004.02.002. View

2.
Urbanska E, Tomczyk T, Haberek G, Pilip S, Matyska J, Turski W . NMDA- but not kainate-mediated events reduce efficacy of some antiepileptic drugs against generalized tonic-clonic seizures in mice. Epilepsia. 1999; 40(11):1507-11. DOI: 10.1111/j.1528-1157.1999.tb02033.x. View

3.
DeLorenzo R, Hauser W, Towne A, Boggs J, Pellock J, Penberthy L . A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996; 46(4):1029-35. DOI: 10.1212/wnl.46.4.1029. View

4.
Walton N, Treiman D . Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. Exp Neurol. 1988; 101(2):267-75. DOI: 10.1016/0014-4886(88)90010-6. View

5.
Lowenstein D . Treatment options for status epilepticus. Curr Opin Pharmacol. 2005; 5(3):334-9. DOI: 10.1016/j.coph.2005.04.003. View